These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33351661)

  • 1. Increasing Access to Buprenorphine in Safety-Net Primary Care Clinics: The New York City Buprenorphine Nurse Care Manager Initiative.
    Kaplan-Dobbs M; Kattan JA; Tuazon E; Jimenez C; Saleh S; Kunins HV
    Am J Public Health; 2021 Feb; 111(2):215-218. PubMed ID: 33351661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "I didn't feel like a number": The impact of nurse care managers on the provision of buprenorphine treatment in primary care settings.
    Beharie N; Kaplan-Dobbs M; Urmanche A; Paone D; Harocopos A
    J Subst Abuse Treat; 2022 Jan; 132():108633. PubMed ID: 34688496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine prescribing practice trends and attitudes among New York providers.
    Kermack A; Flannery M; Tofighi B; McNeely J; Lee JD
    J Subst Abuse Treat; 2017 Mar; 74():1-6. PubMed ID: 28132694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consumer attitudes about opioid addiction treatment: a focus group study in New York City.
    Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO
    J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.
    Polydorou S; Ross S; Coleman P; Duncan L; Roxas N; Thomas A; Mendoza S; Hansen H
    Psychiatr Serv; 2017 Mar; 68(3):295-298. PubMed ID: 27745534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.
    Shah PA; Sohler NL; López C; Fox AD; Cunningham CO
    J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 10. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Shared Medical Appointments to Increase Access to Buprenorphine Treatment.
    Roll D; Spottswood M; Huang H
    J Am Board Fam Med; 2015; 28(5):676-7. PubMed ID: 26355141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
    Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
    Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints.
    Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME
    Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality.
    Gertner AK; Robertson AG; Powell BJ; Jones H; Silberman P; Domino ME
    Health Aff (Millwood); 2020 Aug; 39(8):1395-1404. PubMed ID: 32744950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
    LaBelle CT; Han SC; Bergeron A; Samet JH
    J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study.
    Larochelle MR; Bernson D; Land T; Stopka TJ; Wang N; Xuan Z; Bagley SM; Liebschutz JM; Walley AY
    Ann Intern Med; 2018 Aug; 169(3):137-145. PubMed ID: 29913516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.